This new OTC with ACNU regulatory pathway provides more options for patients in their therapeutic toolbox.
FDA’s DSCSA exemption is the right move
FDA gave drug supply chain trading stakeholders even more time to stabilize electronic connections with their trading partners as they implement DSCSA. This will help avert significant supply chain disruptions and delays in patient access to important medicines.